Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Jiangxi procuratorate prosecuted Gao Zhunhu's suspected bribery case according to law. Recently, Gao Zhunhu (deputy department level), former deputy secretary and vice chairman of Jingdezhen CPPCC in Jiangxi Province, was under the jurisdiction of Jiangxi Provincial People's Procuratorate, and Pingxiang Municipal People's Procuratorate filed a public prosecution with Pingxiang Intermediate People's Court according to law. The case is being further processed. At the stage of examination and prosecution, the procuratorate informed the defendant Gao Zhuhu of his litigation rights according to law, interrogated the defendant according to law and listened to the opinions of the defenders. The Pingxiang Municipal People's Procuratorate sued the accusation: the defendant Gao Zhuhu used to be the secretary, deputy secretary and director of the Party Working Committee of Jingdezhen Ceramic Industrial Park, the secretary of the Party Working Committee of Jingdezhen Central City Changnan Development Zone, the party secretary and chairman of Jingdezhen Urban Construction and Development Investment Co., Ltd., the party secretary and chairman of Jingdezhen Urban Construction Investment Group Co., Ltd., and the party working Committee secretary of Jingdezhen Changnan New District. Jingdezhen High-tech Industrial Development Zone, deputy secretary of the Party Working Committee, director of the management committee and other positions, seek benefits for others, illegally accept other people's property, the amount is particularly huge, and should be investigated for criminal responsibility for accepting bribes according to law.Shanghai Electric established a new company including machinery and equipment sales business. According to the enterprise search APP, Shanghai Dixi New Energy Co., Ltd. was established with Ye Can as its legal representative and registered capital of 1 million yuan. Its business scope includes: power generation business, power transmission business and power supply (distribution) business; Installation, maintenance and testing of power transmission, power supply and power reception facilities; Mechanical equipment sales; Mechanical and electrical equipment sales, etc. Enterprise survey shows that the company is wholly owned by Shanghai Electric New Energy Development Co., Ltd., a subsidiary of Shanghai Electric.
Wuzhou Spring today bought 101 million yuan and sold 140 million yuan on Shanghai Stock Connect. Wuzhou Spring today traded at a daily limit, with a turnover of 4.335 billion yuan and a turnover rate of 35.76%. After-hours data showed that Ningbo Sangtian Road mat bought 77.1945 million yuan, and Shanghai Stock Connect special seats bought 101 million yuan and sold 140 million yuan.Turkish Foreign Minister Fidan discussed the situation in Syria and Gaza with US Secretary of State Blinken. Turkish Foreign Minister Fidan: We discussed the possible roles of Turkey and the United States in Syria in the future. Our primary task is to ensure the stability of Syria and prevent extremist organizations "Islamic State" and the PKK from taking control of Syria.Market News: Due to weak sales in the United States, Nissan halved the output of its Mexican factory.
Villeroi, Governing Committee of the European Central Bank: Interest rates will be cut several times next year. Francois Villeroy de Galhau, a member of the Board of Governors of the European Central Bank, said that the European Central Bank will further reduce borrowing costs in 2025, and there is still a way to go before monetary policy is no longer restrictive. "There will be more interest rate cuts next year, and many times," he said on BFM Business TV on Friday He added that the central bank did not promise the specific interest rate trajectory in advance, but was "quite satisfied with the financial market forecast". The current expectation of the swap market is to cut interest rates by about 120 basis points by the end of next year.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Stock index futures continued to fall, and the main contract of SSE 50 Stock Index Futures (IH) fell by 2.00% in the day, and now it is reported at 2,653.6 points. The main contract of CSI 500 stock index futures (IC) fell by 2.00% in the day and is now reported at 5976.8 points.
Strategy guide 12-14
Strategy guide
12-14
Strategy guide